Literature DB >> 229153

Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing's syndrome.

N O'Mullane, B Walker, J Jefferson, L Hipkin, M Diver, C Davis.   

Abstract

Bromocriptine lowers plasma ACTH levels in patients with pituitary-dependent Cushing's syndrome. It seemed possible that the drug would also be effective in patients who had been adrenalectomised for the disease. The effect of 5.0 mg of bromocriptine on plasma ACTH and prolactin levels in 13 patients, bilaterally adrenalectomised for pituitary-dependent Cushing's syndrome, was therefore studied. In only one patient was a fall in plasma ACTH observed. This may be of doubtful significance since marked spontaneous fluctuation in plasma ACTH levels were found in the five patients tested. Bromocriptine lowered the plasma prolactin in all of the patients, including two with hyperprolactinaemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 229153     DOI: 10.1007/BF03350982

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  4 in total

1.  Bromocriptine for Cushing's disease.

Authors:  A L Kennedy; D A Montgomery
Journal:  Br Med J       Date:  1977-04-23

2.  Effect of bromocriptine in pituitary-dependent Cushing's syndrome.

Authors:  S W Lamberts; J C Birkenhäger
Journal:  J Endocrinol       Date:  1976-08       Impact factor: 4.286

3.  Secretion of prolactin by patients with pituitary and hypothalamic tumors.

Authors:  R W Turkington
Journal:  J Clin Endocrinol Metab       Date:  1972-01       Impact factor: 5.958

4.  Nyctohemeral variation and suppressibility of plasma ACTH in various stages of Cushing's disease.

Authors:  D M Cook; J W Kendall; J P Allen; L G Lagerquist
Journal:  Clin Endocrinol (Oxf)       Date:  1976-07       Impact factor: 3.478

  4 in total
  4 in total

1.  Long term bromocriptine therapy in Cushing's disease.

Authors:  L P Kapcala; I M Jackson
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

2.  Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro.

Authors:  M Ishibashi; T Yamaji
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

3.  Effects of bromocriptine on pituitary tumour size.

Authors:  A M McGregor; M F Scanlon; R Hall; K Hall
Journal:  Br Med J       Date:  1979-09-22

4.  Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.

Authors:  Martin Reincke; Adriana Albani; Guillaume Assie; Irina Bancos; Thierry Brue; Michael Buchfelder; Olivier Chabre; Filippo Ceccato; Andrea Daniele; Mario Detomas; Guido Di Dalmazi; Atanaska Elenkova; James Findling; Ashley B Grossman; Celso E Gomez-Sanchez; Anthony P Heaney; Juergen Honegger; Niki Karavitaki; Andre Lacroix; Edward R Laws; Marco Losa; Masanori Murakami; John Newell-Price; Francesca Pecori Giraldi; Luis G Pérez-Rivas; Rosario Pivonello; William E Rainey; Silviu Sbiera; Jochen Schopohl; Constantine A Stratakis; Marily Theodoropoulou; Elisabeth F C van Rossum; Elena Valassi; Sabina Zacharieva; German Rubinstein; Katrin Ritzel
Journal:  Eur J Endocrinol       Date:  2021-03       Impact factor: 6.664

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.